FDA Brief

Warning letters Drugs

FDA warning letter to

MMC Healthcare Ltd.

High riskIssued Sep 24, 2024Posted Oct 8, 2024Center for Drug Evaluation and Research (CDER)

FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.

What happened

FDA inspected MMC Healthcare Ltd.'s drug manufacturing facility at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024. FDA found process validation reports with added data, backdated signatures, and replaced pages; a UV-Vis (ultraviolet-visible) computer system used for release testing lacked an audit trail (a record of changes) and defined user access levels. FDA also found microbial test methods that differed from USP (United States Pharmacopeia) methods and lacked validation data.

What FDA found

  1. The quality unit did not have adequate authority or controls, as shown by process validation reports with added data, backdated signatures, and replaced pages.

    21 CFR 211.22(a)
  2. The ultraviolet-visible (UV-Vis) computer system used for release testing lacked an audit trail (a record of changes) and defined user access levels.

    21 CFR 211.68(b)
  3. The company did not use USP (United States Pharmacopeia) methods for multiple products and could not provide data showing its alternate methods were validated or equivalent.

    21 CFR 211.165(e)

What FDA wants

FDA asks MMC to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. If it cannot complete corrective actions in that time, it must state why and give a completion schedule.

Who should pay attention

  • brands and distributors that buy MMC drug products
  • drug manufacturers that rely on paper or electronic records for release testing
  • quality teams at India-based contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk